Analysis of Prevalence and Factors of Potential Drug-Drug Interactions in Hypertensive Patients the Coastal Area of Surabaya
Article Sidebar
Main Article Content
Page: 2924-2929
Abstract
Hypertension is a severe health problem that generally requires combination therapy. Using a combination of antihypertensive therapy and long-term therapy requires monitoring the effects of potential drug-drug interactions (PDDIs) experienced by patients. This study aims to determine the drug interaction profile related to severity and mechanism. The method was descriptive and observational by recapitulating the prescription in several pharmacies in the coastal area of Surabaya. The samples are prescriptions consist of antihypertensives with other drugs. This research was conducted for three months. This study showed that 43% potential drug-drug interactions. The pharmacodynamic interactions are slightly more dominant (49%) than pharmacokinetics (45%). Meanwhile, the highest severity of drug interactions, namely minor (49%), followed by moderate (39%) and severe (12%), was in the last position. The modest drug interaction at a moderate level is amlodipine, which can decrease the pharmacological effect of metformin. Therefore, pharmacists need to monitor blood sugar levels regularly. Serious interactions are indeed the lowest incidence; otherwise, the effects can be dangerous, so pharmacists need to monitor patients who receive drugs with severe drug interactions. One of them is amlodipine and simvastatin, which can increase the risk of rhabdomyolysis from statins. Pharmacists have an important role in monitoring the effects of drug interactions in hypertensive patients. Patients get the maximum therapeutic effect with minimal drug interactions or prevent drug interactions.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Rasool, M. F., Rehman, A. U., Khan, I., Latif, M., Ahmad, I., Shakeel, S., Sadiq, M., Hayat, K., Shah, S., Ashraf, W., Majeed, A., Hussain, I., & Hussain, R. Assessment of risk factors associated with potential drug-drug interactions among patients suffering from chronic disorders. PloS one, 2023, 18(1), e0276277. https://doi.org/10.1371/journal.pone.0276277 DOI: https://doi.org/10.1371/journal.pone.0276277
Song, Y. K., & Oh, J. M. Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, 28(8), 3711–3720. https://doi.org/10.1007/s00520-019-05221-1 DOI: https://doi.org/10.1007/s00520-019-05221-1
Daggupati, S. J. V., Saxena, P. U. P., Kamath, A., & Chowta, M. N. Drug-drug interactions in patients undergoing chemoradiotherapy and the impact of an expert team intervention. International journal of clinical pharmacy, 2020, 42(1), 132–140. https://doi.org/10.1007/s11096-019-00949-6 DOI: https://doi.org/10.1007/s11096-019-00949-6
Medina-Barajas, F., Vázquez-Méndez, E., Pérez-Guerrero, E. E., Sánchez-López, V. A., Hernández-Cañaveral, I. I., Gabriel A, R. O., & Huerta-Olvera, S. G. Pilot study: Evaluation of potential drug-drug interactions in hospitalized pediatric patients. Pediatrics and neonatology, 2020, 61(3), 279–289. https://doi.org/10.1016/j.pedneo.2019.11.006 DOI: https://doi.org/10.1016/j.pedneo.2019.11.006
McGettigan, S., Curtin, D., O’Mahony, D. Adverse Drug Reactions in Multimorbid Older People Exposed to Polypharmacy: Epidemiology and Prevention. Pharmacoepidemiology, 2024, 3, 208-222. https://doi.org/10.3390/pharma3020013 DOI: https://doi.org/10.3390/pharma3020013
Ismail, M., Khan, F., Noor, S., Haider, I., Haq, I. U., Ali, Z., Shah, Z., & Hassam, M. Potential drug-drug interactions in medical intensive care unit of a tertiary care hospital in Pakistan. International journal of clinical pharmacy, 2016, 38(5), 1052–1056. https://doi.org/10.1007/s11096-016-0340-3 DOI: https://doi.org/10.1007/s11096-016-0340-3
Janković, S. M., Pejčić, A. V., Milosavljević, M. N., Opančina, V. D., Pešić, N. V., Nedeljković, T. T., & Babić, G. M. Risk factors for potential drug-drug interactions in intensive care unit patients. Journal of critical care, 2018, 43, 1–6. https://doi.org/10.1016/j.jcrc.2017.08.021 DOI: https://doi.org/10.1016/j.jcrc.2017.08.021
Tavousi, F., Sadeghi, A., Darakhshandeh, A., & Moghaddas, A. Potential Drug-drug Interactions at a Referral Pediatric Oncology Ward in Iran: A Cross-sectional Study. Journal of pediatric hematology/oncology, 2019, 41(3), e146–e151. https://doi.org/10.1097/MPH.0000000000001346 DOI: https://doi.org/10.1097/MPH.0000000000001346
Nightingale, G., Pizzi, L. T., Barlow, A., Barlow, B., Jacisin, T., McGuire, M., Swartz, K., & Chapman, A. The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software. Journal of geriatric oncology, 2018, 9(5), 526–533. https://doi.org/10.1016/j.jgo.2018.02.001 DOI: https://doi.org/10.1016/j.jgo.2018.02.001
Lima, E. D. C., Camarinha, B. D., Ferreira Bezerra, N. C., Panisset, A. G., Belmino de Souza, R., Silva, M. T., & Lopes, L. C. Severe Potential Drug-Drug Interactions and the Increased Length of Stay of Children in Intensive Care Unit. Frontiers in pharmacology, 2020, 11, 555407. https://doi.org/10.3389/fphar.2020.555407 DOI: https://doi.org/10.3389/fphar.2020.555407
Ramasubbu, S. K., Mahato, S. K., Agnihotri, A., Pasricha, R. K., Nath, U. K., & Das, B., Dr. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital. Cancer treatment and research communications, 2021, 26, 100277. https://doi.org/10.1016/j.ctarc.2020.100277 DOI: https://doi.org/10.1016/j.ctarc.2020.100277
Ismail, M., Noor, S., Harram, U., Haq, I., Haider, I., Khadim, F., Khan, Q., Ali, Z., Muhammad, T., & Asif, M. Potential drug-drug interactions in outpatient department of a tertiary care hospital in Pakistan: a cross-sectional study. BMC health services research, 2018, 18(1), 762. https://doi.org/10.1186/s12913-018-3579-7 DOI: https://doi.org/10.1186/s12913-018-3579-7
Nusair, M. B., Al-Azzam, S. I., Arabyat, R. M., Amawi, H. A., Alzoubi, K. H., & Rabah, A. A. The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2020, 28(2), 155–160. https://doi.org/10.1016/j.jsps.2019.11.009 DOI: https://doi.org/10.1016/j.jsps.2019.11.009
Abbas, A., Al-Shaibi, S., Sankaralingam, S., Awaisu, A., Kattezhathu, V. S., Wongwiwatthananukit, S., & Owusu, Y. B. Determination of potential drug-drug interactions in prescription orders dispensed in a community pharmacy setting using Micromedex®and Lexicomp®: a retrospective observational study. International journal of clinical pharmacy, 2022, 44(2), 348–356. https://doi.org/10.1007/s11096-021-01346-8 DOI: https://doi.org/10.1007/s11096-021-01346-8
Hughes, J. E., Russo, V., Walsh, C., Menditto, E., Bennett, K., & Cahir, C. Prevalence and Factors Associated with Potential Drug-Drug Interactions in Older Community-Dwelling Adults: A Prospective Cohort Study. Drugs & aging, 2021, 38(11), 1025–1037. https://doi.org/10.1007/s40266-021-00898-8 DOI: https://doi.org/10.1007/s40266-021-00898-8
Reyaan, I. B. M., Kuning, C., & Adnyana, I. K. Studi Potensi Interaksi Obat pada Resep Polifarmasi di Dua Apotek Kota Bandung. Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice) 2021, 11, 145 DOI: https://doi.org/10.22146/jmpf.56931
Ren, W., Liu, Y., Zhang, J., Fang, Z., Fang, H., Gong, Y., & Lv, X. Prevalence of potential drug-drug interactions in outpatients of a general hospital in China: a retrospective investigation. International journal of clinical pharmacy, 2020, 42(4), 1190–1196. https://doi.org/10.1007/s11096-020-01068-3 DOI: https://doi.org/10.1007/s11096-020-01068-3
Haq, I. et al. Prevalence, predictors and outcomes of potential drug-drug interactions in left ventricular failure: Considerable factors for quality use of medicines. Brazilian Journal of Pharmaceutical Sciences 2020, 56, 1–17 DOI: https://doi.org/10.1590/s2175-97902020000218326
Wastesson, J. W., Canudas-Romo, V., Lindahl-Jacobsen, R., & Johnell, K. Remaining Life Expectancy With and Without Polypharmacy: A Register-Based Study of Swedes Aged 65 Years and Older. Journal of the American Medical Directors Association, 2016, 17(1), 31–35. https://doi.org/10.1016/j.jamda.2015.07.015 DOI: https://doi.org/10.1016/j.jamda.2015.07.015
Bojuwoye, A. O., Suleman, F., & Perumal-Pillay, V. A. Polypharmacy and the occurrence of potential drug-drug interactions among geriatric patients at the outpatient pharmacy department of a regional hospital in Durban, South Africa. Journal of pharmaceutical policy and practice, 2022, 15(1), 1. https://doi.org/10.1186/s40545-021-00401-z DOI: https://doi.org/10.1186/s40545-021-00401-z
Gari, M., Debbarma, R. R., Majhee, L. & Choudhury, S. Effect of amlodipine on blood glucose level in euglycemic and streptozotocin induced diabetic Albino rats and its pharmacodynamic interaction with glibenclamide. Int J Basic Clin Pharmacol 2017, 6, 1650 DOI: https://doi.org/10.18203/2319-2003.ijbcp20172724
Subramanian, A., Adhimoolam, M., & Kannan, S. Study of drug-Drug interactions among the hypertensive patients in a tertiary care teaching hospital. Perspectives in clinical research, 2018, 9(1), 9–14. https://doi.org/10.4103/picr.PICR_145_16 DOI: https://doi.org/10.4103/picr.PICR_145_16
Benoist, G. E. et al. Drug–drug interaction potential in men treated with enzalutamide: Mind the gap. Br J Clin Pharmacol 2018; 84, 122–129 DOI: https://doi.org/10.1111/bcp.13425
Dumbreck, S. et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 2015; 350. DOI: https://doi.org/10.1136/bmj.h949